A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266090	PMC
http://dx.doi.org/10.1093/annonc/mdv477	DOI Listing

Publication Analysis

phase ii/iii

ii/iii randomized

randomized study

study compare

compare efficacy

efficacy safety

safety rigosertib

rigosertib gemcitabine

gemcitabine versus

versus gemcitabine

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!